Home » Uncategorized » M2D2 Finalists: Meet Dr. Atharva Poundarik and Robert Hoy, founders of OrthoGraft

M2D2 Finalists: Meet Dr. Atharva Poundarik and Robert Hoy, founders of OrthoGraft

The Massachusetts Medical Device Development Center (M2D2) is in the midst of its 2014 New Venture Competition. After weeks of pitches, fifteen finalists have been announced. These finalists have business ventures that M2D2 has deemed “disruptive.” With these fifteen blogs posts, MedTech Boston gives readers a glimpse of the innovators that made it this far in the M2D2 New Venture Competition.

Dr. Atharva Poundarik and Robert Hoy – OrthoGraft

Dr. Atharva Poundarik

Dr. Atharva Poundarik

Robert Hoy

Robert Hoy

Dr. Atharva Poundarik and Robert Hoy make up one of the teams that will move on to the next round of judging in the M2D2 contest. Their company, OrthoGraft, was chosen from the pool of applicants because of its true potential to disrupt medicine.

What is OrthoGraft all about? Poundarik and Hoy describe their company in a MedTech Boston Q&A:

1. Briefly describe your technology

At OrthoGraft we are developing biomaterials that stimulate the regeneration of bone by a novel mechanism known as osteoinductive nanoarchitecture. Our processing technique combines the two principal components of bone, collagen and hydroxyapatite, in the presence of naturally occurring designer proteins, to impart a structure and composition nearly identical to that of natural bone.

2. How does it add value to a clinical environment?

Our biomaterials utilize a structural mechanism through which bone growth is achieved, decreasing the reliance on the chemical stimulation seen in current products. We believe that since our natural bone relies on both structural and chemical cues for healing, we cannot maximize our healing potential until we create biomaterials that utilize both mechanisms.

3. How is it disruptive?

Our technology is disruptive because it opens the door to a new mode of healing in bone substitutes without disrupting the regulatory or reimbursement landscapes. Our therapeutic effect comes from the nanostructure and composition of hydroxyapatite, a material widely used in bone substitutes, making our regulatory and reimbursement pathways well established.

4. What is your target market?

Our target market is for patients who have bone defects in the spine, extremities, and pelvis. The largest need exists in the spinal market where our material will be used in spinal fusions, a procedure which is performed over 3 million times annually, for patients suffering from degenerative disc disease.

5. What are your anticipated funding needs?

We are currently seeking a seed fund of $250,000 to complete our first small animal studies.

Congratulations and good luck to OrthoGraft, and be sure to stay tuned to catch the other 14 finalists winners featured on MedTech Boston!

M2D2 will be hosting the 2014 New Venture Competition Showcase Event on Wednesday, March 26, 2014. Novel medical device technologies will be presented, followed by a poster and networking session. The grand prize winner will be announced at the follow up winner’s ceremony on April 8th at the offices of Nutter McClennen & Fish in Boston from 4 pm to 8 pm.

Sony Salzman

Sony Salzman

    At MedTechBoston, we are sharing stories about cutting-edge medical innovation. As Managing Editor, I help coordinate our coverage of hackathons and company profiles. I also create content, update our social media and scout stories. I'm part of an ambitious group of people hoping to inspire a tech revolution in medical care.

    Similar posts

    Follow us!

    Send this to a friend